IL264692A - - Google Patents
Info
- Publication number
- IL264692A IL264692A IL26469219A IL26469219A IL264692A IL 264692 A IL264692 A IL 264692A IL 26469219 A IL26469219 A IL 26469219A IL 26469219 A IL26469219 A IL 26469219A IL 264692 A IL264692 A IL 264692A
- Authority
- IL
- Israel
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5434—IL-12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/208—IL-12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
- Y02E60/00—Enabling technologies; Technologies with a potential or indirect contribution to GHG emissions mitigation
- Y02E60/10—Energy storage using batteries
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Endocrinology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Reproductive Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20160101823 | 2016-08-10 | ||
| PCT/KR2017/008676 WO2018030806A1 (ko) | 2016-08-10 | 2017-08-10 | 항체 중쇄불변부위 이종이중체에 융합된 사이토카인 및 이를 포함하는 약제학적 조성물 |
| KR1020170101594A KR102050463B1 (ko) | 2016-08-10 | 2017-08-10 | 항체 중쇄불변부위 이종이중체 (heterodimeric Fc)에 융합된 사이토카인 (heterodimeric Fc-fused cytokine) 및 이를 포함하는 약제학적 조성물 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL264692A true IL264692A (OSRAM) | 2019-04-30 |
| IL264692B1 IL264692B1 (en) | 2025-08-01 |
| IL264692B2 IL264692B2 (en) | 2025-12-01 |
Family
ID=61524969
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL264692A IL264692B2 (en) | 2016-08-10 | 2019-02-06 | Heterodimeric cytokine fused to FC and pharmaceutical preparation containing the same |
Country Status (14)
| Country | Link |
|---|---|
| US (4) | US10696722B2 (OSRAM) |
| EP (2) | EP3511340B1 (OSRAM) |
| JP (3) | JP6993403B2 (OSRAM) |
| KR (4) | KR102050463B1 (OSRAM) |
| CN (1) | CN110267977A (OSRAM) |
| AU (2) | AU2017310163B2 (OSRAM) |
| BR (1) | BR112019002394B1 (OSRAM) |
| CA (1) | CA3033475A1 (OSRAM) |
| DK (1) | DK3511340T3 (OSRAM) |
| ES (1) | ES3000558T3 (OSRAM) |
| IL (1) | IL264692B2 (OSRAM) |
| MX (2) | MX386014B (OSRAM) |
| SG (1) | SG11201901071TA (OSRAM) |
| ZA (1) | ZA201900772B (OSRAM) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3511340T3 (da) | 2016-08-10 | 2025-01-02 | Univ Ajou Ind Academic Coop Found | Heterodimerisk fc-fusioneret cytokin og farmaceutisk sammensætning omfattende det samme |
| WO2019010219A1 (en) | 2017-07-03 | 2019-01-10 | Torque Therapeutics, Inc. | IMMUNOSTIMULATORY FUSION MOLECULES AND USES THEREOF |
| CN111356524B (zh) | 2018-02-14 | 2022-03-15 | 株式会社Lg化学 | 催化剂填充方法和使用该方法制备丁二烯的方法 |
| CN110396133B (zh) * | 2018-04-25 | 2021-07-23 | 免疫靶向有限公司 | 一种以白介素12为活性成分的融合蛋白型药物前体 |
| KR102884523B1 (ko) * | 2018-10-03 | 2025-11-10 | 젠코어 인코포레이티드 | IL-12 이종이량체 Fc-융합 단백질 |
| TWI891611B (zh) | 2018-10-23 | 2025-08-01 | 美商蜻蜓醫療公司 | 異二聚體fc融合蛋白 |
| AU2020358979A1 (en) | 2019-10-03 | 2022-04-21 | Xencor, Inc. | Targeted IL-12 heterodimeric Fc-fusion proteins |
| WO2021216916A1 (en) * | 2020-04-22 | 2021-10-28 | Dragonfly Therapeutics, Inc. | Formulation, dosage regimen, and manufacturing process for heterodimeric fc-fused proteins |
| CA3207821A1 (en) * | 2020-12-10 | 2022-06-16 | Invenra Inc. | Orthogonal mutations for heterodimerization |
| MX2024004763A (es) | 2021-10-20 | 2024-05-08 | Synthekine Inc | Citocinas heterodimericas fc y usos de las mismas. |
| KR102796245B1 (ko) * | 2022-05-10 | 2025-04-18 | 아주대학교산학협력단 | 인터루킨21 변이체, 이를 포함하는 융합단백질 및 이의 용도 |
| WO2024086739A1 (en) | 2022-10-20 | 2024-04-25 | Synthekine, Inc. | Methods and compositions of il12 muteins and il2 muteins |
| WO2024094755A1 (en) * | 2022-11-02 | 2024-05-10 | Synerkine Pharma B.V. | Engineered immunocytokines, fusion polypeptides, and il10 polypeptides |
| CN119768414A (zh) * | 2022-11-10 | 2025-04-04 | 康立泰生物医药(青岛)有限公司 | 聚乙二醇定点修饰异源聚体蛋白或多肽及其制备方法与应用 |
| WO2024249320A1 (en) * | 2023-05-26 | 2024-12-05 | University Of Florida Research Foundation, Incorporated | In vivo optimization of biologics |
| CN117986386B (zh) * | 2024-02-06 | 2024-11-29 | 康立泰生物医药(青岛)有限公司 | 重组人白细胞介素-35及其制备方法和应用 |
Family Cites Families (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4722848A (en) | 1982-12-08 | 1988-02-02 | Health Research, Incorporated | Method for immunizing animals with synthetically modified vaccinia virus |
| EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
| US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5849589A (en) | 1996-03-11 | 1998-12-15 | Duke University | Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells |
| US7951917B1 (en) | 1997-05-02 | 2011-05-31 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
| PT1037927E (pt) | 1997-12-08 | 2004-10-29 | Emd Lexigen Res Ct Corp | Proteinas de fusao heterodimericas uteis para imunoterapia de abordagem selectiva e estimulacao imunologica geral |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| US7183387B1 (en) | 1999-01-15 | 2007-02-27 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US6864235B1 (en) | 1999-04-01 | 2005-03-08 | Eva A. Turley | Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans |
| WO2002024223A2 (en) | 2000-09-21 | 2002-03-28 | The Brigham And Women's Hospital, Inc. | Prevention and treatment of streptococcal and staphylococcal infection |
| US8192744B2 (en) | 2002-08-26 | 2012-06-05 | Ibcc Holding As | Drug for treating states related to the inhibition of angiogenesis and/or endothelial cell proliferation |
| WO2005114186A1 (ja) | 2004-05-20 | 2005-12-01 | Wako Pure Chemical Industries, Ltd. | ヒアルロン酸バインディングプロテインを用いたヒアルロン酸の測定方法 |
| CA2610791C (en) | 2005-06-08 | 2015-12-01 | Cangene Corporation | Hyaluronic acid binding peptides enhance host defense against pathogenic bacteria |
| RS54271B1 (sr) | 2005-07-01 | 2016-02-29 | E. R. Squibb & Sons, L.L.C. | Humana monoklonska antitela za ligand programirane smrti 1 (pd-l1) |
| EP1999154B1 (en) | 2006-03-24 | 2012-10-24 | Merck Patent GmbH | Engineered heterodimeric protein domains |
| US8163498B2 (en) | 2006-08-08 | 2012-04-24 | Seikagaku Corporation | Method for determination of molecular weight of hyaluronic acid |
| WO2008089448A2 (en) | 2007-01-19 | 2008-07-24 | Cornell Presearch Foundation, Inc. | Methods and compositions for promoting survival & proliferation of endothelial cells & stimulating angiogenesis |
| WO2009089004A1 (en) | 2008-01-07 | 2009-07-16 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
| BRPI0906309A2 (pt) | 2008-04-02 | 2020-05-26 | Macrogenics, Inc | Imunoglobulina, anticorpo, uso do anticorpo e composição farmacêutica |
| EP2270145B1 (en) | 2008-04-15 | 2013-01-16 | Wako Pure Chemical Industries, Ltd. | Novel protein capable of binding to hyaluronic acid, and method for measurement of hyaluronic acid using the same |
| CA2749200A1 (en) | 2009-01-29 | 2010-08-05 | Michael Bowen | Human anti-il-6 antibodies with extended in vivo half-life and their use in treatment of oncology, autoimmune diseases and inflammatory diseases |
| BRPI1012589A2 (pt) | 2009-04-07 | 2016-03-22 | Roche Glycart Ag | anticorpos bi-específicos anti-erbb-3/anti-c-met |
| CA2769619C (en) | 2009-08-17 | 2019-04-30 | Roche Glycart Ag | Targeted immunoconjugates |
| US9493578B2 (en) | 2009-09-02 | 2016-11-15 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
| PL2560993T3 (pl) | 2010-04-20 | 2024-11-04 | Genmab A/S | Heterodimeryczne białka zawierające region FC przeciwciała i sposoby ich wytwarzania |
| KR101860963B1 (ko) | 2010-04-23 | 2018-05-24 | 제넨테크, 인크. | 이종다량체 단백질의 생산 |
| EP2609111B1 (en) | 2010-08-24 | 2017-11-01 | F. Hoffmann-La Roche AG | Bispecific antibodies comprising a disulfide stabilized-fv fragment |
| WO2012032080A1 (en) | 2010-09-07 | 2012-03-15 | F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H | Stabilised human fc |
| WO2012051147A1 (en) | 2010-10-11 | 2012-04-19 | Abbott Laboratories | Processes for purification of proteins |
| RS59589B1 (sr) | 2010-11-05 | 2019-12-31 | Zymeworks Inc | Dizajniranje stabilnog heterodimernog antitela sa mutacijama u fc domenu |
| MX349057B (es) | 2010-11-30 | 2017-07-07 | Chugai Pharmaceutical Co Ltd | Agente terapeutico que induce citotoxicidad. |
| US10689447B2 (en) | 2011-02-04 | 2020-06-23 | Genentech, Inc. | Fc variants and methods for their production |
| EP2673294B1 (en) | 2011-02-10 | 2016-04-27 | Roche Glycart AG | Mutant interleukin-2 polypeptides |
| KR20160044598A (ko) | 2011-03-29 | 2016-04-25 | 로슈 글리카트 아게 | 항체 Fc 변이체 |
| EA201892619A1 (ru) | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
| PT2714718T (pt) | 2011-05-24 | 2017-04-19 | Symic Ip Llc | Preparação e métodos de utilização de peptidoglicanas sintéticas que se ligam a ácido hialurónico |
| WO2013012733A1 (en) | 2011-07-15 | 2013-01-24 | Biogen Idec Ma Inc. | Heterodimeric fc regions, binding molecules comprising same, and methods relating thereto |
| ES2888249T3 (es) | 2011-10-11 | 2022-01-03 | Univ Zuerich | Medicamento de combinación que comprende IL-12 y un agente para el bloqueo de moléculas inhibidoras de linfocitos T para terapia tumoral |
| US9795686B2 (en) | 2012-01-19 | 2017-10-24 | The Johns Hopkins University | Biomaterials comprising hyaluronic acid binding peptides and bifunctional biopolymer molecules for hyaluronic acid retention and tissue engineering applications |
| CA2870821C (en) | 2012-04-20 | 2022-06-14 | Merus B.V. | Methods and means for the production of ig-like molecules |
| US9751919B2 (en) | 2012-05-04 | 2017-09-05 | Emergent Biosolutions Canada Inc. | Antimicrobial compositions comprising a hyaluronic acid binding peptide and a β-lactam antibiotic |
| WO2014020069A1 (en) | 2012-08-02 | 2014-02-06 | F. Hoffmann-La Roche Ag | Method for producing monomeric and multimeric molecules and uses thereof |
| MX2015000681A (es) | 2012-08-02 | 2015-04-10 | Hoffmann La Roche | Metodo para producir receptores de fc (fcr) solubles como fusion de fc con region de fc de inmunoglobulina inerte y uso de las mismas. |
| AR092044A1 (es) | 2012-08-07 | 2015-03-18 | Roche Glycart Ag | Inmunoterapia mejorada |
| JP6273205B2 (ja) | 2012-10-05 | 2018-01-31 | 協和発酵キリン株式会社 | ヘテロダイマータンパク質組成物 |
| KR101522954B1 (ko) * | 2012-11-27 | 2015-05-27 | 아주대학교산학협력단 | 항체 중쇄불변부위의 이종이중체 고효율 형성을 유도하는 ch3 도메인 변이체 쌍, 이의 제조방법, 및 용도 |
| ES2821753T3 (es) | 2013-03-15 | 2021-04-27 | Lilly Co Eli | Procedimientos de producción de Fab y de anticuerpos biespecíficos |
| US10160793B2 (en) | 2013-03-15 | 2018-12-25 | Genentech, Inc. | Methods of treating inflammatory bowel disease using IL-22 Fc fusion proteins |
| US20140302037A1 (en) | 2013-03-15 | 2014-10-09 | Amgen Inc. | BISPECIFIC-Fc MOLECULES |
| DK2970486T3 (en) * | 2013-03-15 | 2018-08-06 | Xencor Inc | MODULATION OF T-CELLS WITH BISPECIFIC ANTIBODIES AND FC-FUSIONS |
| KR102266819B1 (ko) | 2013-04-29 | 2021-06-18 | 에프. 호프만-라 로슈 아게 | Fc-수용체 결합 개질된 비대칭 항체 및 이의 사용 방법 |
| AR096891A1 (es) | 2013-07-12 | 2016-02-03 | Hanmi Pharm Ind Co Ltd | Conjugado de monómero polipéptido biológicamente activo y conjugado de fragmento fc de inmunoglobulina, que muestra aclaramiento mediado por receptor reducido, y el método para la preparación del mismo |
| UA117289C2 (uk) | 2014-04-02 | 2018-07-10 | Ф. Хоффманн-Ля Рош Аг | Мультиспецифічне антитіло |
| MX2016014409A (es) | 2014-05-06 | 2017-01-20 | Genentech Inc | Produccion de proteinas heteromultimericas usando celulas de mamifero. |
| KR101721295B1 (ko) | 2014-06-11 | 2017-04-10 | 주식회사 엘지화학 | 염화비닐계 수지의 제조방법 |
| EP3161002A1 (en) | 2014-06-27 | 2017-05-03 | Innate Pharma | MULTISPECIFIC NKp46 BINDING PROTEINS |
| BR112017006178A2 (pt) | 2014-11-06 | 2018-05-02 | F. Hoffmann-La Roche Ag | região fc, anticorpos, formulação farmacêutica e usos dos anticorpos |
| BR112017006591A2 (pt) | 2014-11-06 | 2018-01-16 | Hoffmann La Roche | polipeptídeo heterodimérico, formulação farmacêutica e uso de um polipeptídeo heterodimérico |
| CN104628870A (zh) * | 2015-02-04 | 2015-05-20 | 中国药科大学 | 一种人IL12Rβ1-CHR蛋白及其Fc融合蛋白 |
| IL294679B2 (en) | 2015-08-07 | 2023-10-01 | Alx Oncology Inc | Structures with a SIRP-alpha site or its variant |
| MX389194B (es) | 2015-10-06 | 2025-03-20 | Univ Minnesota | Compuestos terapéuticos y métodos. |
| KR101851380B1 (ko) | 2015-10-12 | 2018-04-23 | 아주대학교산학협력단 | 효모접합을 이용한 항체 ch3 도메인 이종이중체 돌연변이쌍 제조 방법 및 이에 의하여 제조된 ch3 돌연변이체 쌍 |
| WO2018007314A1 (en) | 2016-07-04 | 2018-01-11 | F. Hoffmann-La Roche Ag | Novel antibody format |
| WO2018030806A1 (ko) | 2016-08-10 | 2018-02-15 | 아주대학교산학협력단 | 항체 중쇄불변부위 이종이중체에 융합된 사이토카인 및 이를 포함하는 약제학적 조성물 |
| DK3511340T3 (da) | 2016-08-10 | 2025-01-02 | Univ Ajou Ind Academic Coop Found | Heterodimerisk fc-fusioneret cytokin og farmaceutisk sammensætning omfattende det samme |
| KR101928981B1 (ko) | 2016-09-02 | 2018-12-13 | 고려대학교 산학협력단 | 항체 중쇄불변부위 이종이중체 (heterodimeric Fc)에 융합된 IL-21 (heterodimeric Fc-fused IL-21) 및 이를 포함하는 약제학적 조성물 |
| SG11201903302UA (en) | 2016-10-14 | 2019-05-30 | Xencor Inc | Bispecific heterodimeric fusion proteins containing il-15/il-15ralpha fc-fusion proteins and pd-1 antibody fragments |
| SG11201907646YA (en) | 2017-02-20 | 2019-09-27 | Dragonfly Therapeutics Inc | Proteins binding her2, nkg2d and cd16 |
| CA3056837A1 (en) | 2017-03-27 | 2018-10-04 | F. Hoffmann-La Roche Ag | Improved antigen binding receptors |
| US11547957B2 (en) | 2017-05-11 | 2023-01-10 | Emd Millipore Corporation | Method of maintaining narrow residence time distributions in continuous flow systems |
| US10676516B2 (en) | 2017-05-24 | 2020-06-09 | Pandion Therapeutics, Inc. | Targeted immunotolerance |
| JP2020525445A (ja) | 2017-06-21 | 2020-08-27 | セファロン・インコーポレイテッドＣｅｐｈａｌｏｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ | カチオン交換クロマトグラフィーの洗浄緩衝液 |
| JP2019014449A (ja) | 2017-07-10 | 2019-01-31 | トヨタ自動車株式会社 | 車両用動力伝達装置 |
| KR20240167101A (ko) | 2017-09-07 | 2024-11-26 | 드래곤플라이 쎄라퓨틱스, 인크. | Nkg2d, cd16 및 넥틴4에 결합하는 단백질 |
| MX2020003211A (es) | 2017-09-21 | 2020-09-21 | Merck Patent Gmbh | Proteina de fusion que comprende una porcion de fgf-18. |
| KR102839644B1 (ko) | 2017-09-22 | 2025-07-31 | 우시 바이올로직스 아일랜드 리미티드 | 신규한 이중특이적 폴리펩티드 복합체 |
| TW201932142A (zh) | 2017-10-20 | 2019-08-16 | 瑞士商赫孚孟拉羅股份公司 | 自單特異性抗體產生多特異性抗體之方法 |
| BR112021000392A2 (pt) | 2018-07-11 | 2021-04-06 | Momenta Pharmaceuticals, Inc. | Composições e métodos relacionados a construtos do domínio de ligação fc-antígeno manipulados |
| KR102884523B1 (ko) | 2018-10-03 | 2025-11-10 | 젠코어 인코포레이티드 | IL-12 이종이량체 Fc-융합 단백질 |
| TWI891611B (zh) | 2018-10-23 | 2025-08-01 | 美商蜻蜓醫療公司 | 異二聚體fc融合蛋白 |
-
2017
- 2017-08-10 DK DK17839824.4T patent/DK3511340T3/da active
- 2017-08-10 CA CA3033475A patent/CA3033475A1/en active Pending
- 2017-08-10 CN CN201780062851.0A patent/CN110267977A/zh active Pending
- 2017-08-10 EP EP17839824.4A patent/EP3511340B1/en active Active
- 2017-08-10 ES ES17839824T patent/ES3000558T3/es active Active
- 2017-08-10 KR KR1020170101594A patent/KR102050463B1/ko active Active
- 2017-08-10 SG SG11201901071TA patent/SG11201901071TA/en unknown
- 2017-08-10 US US16/323,839 patent/US10696722B2/en active Active
- 2017-08-10 EP EP24194198.8A patent/EP4470552A3/en active Pending
- 2017-08-10 MX MX2019001651A patent/MX386014B/es unknown
- 2017-08-10 JP JP2019506697A patent/JP6993403B2/ja active Active
- 2017-08-10 AU AU2017310163A patent/AU2017310163B2/en active Active
- 2017-08-10 BR BR112019002394-1A patent/BR112019002394B1/pt active IP Right Grant
-
2019
- 2019-02-06 IL IL264692A patent/IL264692B2/en unknown
- 2019-02-06 ZA ZA2019/00772A patent/ZA201900772B/en unknown
- 2019-02-08 MX MX2021010809A patent/MX2021010809A/es unknown
- 2019-11-25 KR KR1020190152270A patent/KR102416411B1/ko active Active
-
2020
- 2020-05-28 US US16/886,177 patent/US11078249B2/en active Active
- 2020-05-28 US US16/886,184 patent/US11692019B2/en active Active
-
2021
- 2021-03-03 JP JP2021033816A patent/JP7111855B2/ja active Active
- 2021-11-26 AU AU2021273642A patent/AU2021273642B2/en active Active
-
2022
- 2022-06-29 KR KR1020220079686A patent/KR102607285B1/ko active Active
- 2022-07-21 JP JP2022116329A patent/JP7488854B2/ja active Active
-
2023
- 2023-05-24 US US18/323,124 patent/US12358964B2/en active Active
- 2023-11-23 KR KR1020230164332A patent/KR102652247B1/ko active Active